Serofit50 mg

Serofit is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of the following conditions:

Established / FDA-approved indications

• Major Depressive Disorder (MDD) in adults.
• Obsessive-Compulsive Disorder (OCD) in adults and pediatric patients (6 years and older).
• Panic Disorder, with or without agoraphobia, in adults.
• Post-Traumatic Stress Disorder (PTSD) in adults.
• Social Anxiety Disorder (Social Phobia) in adults.
• Premenstrual Dysphoric Disorder (PMDD) in adults, either continuously or dosed only during the luteal phase of the menstrual cycle.

Off-label uses (used in practice but not a formal labeled indication)

• Generalized anxiety disorder (used off-label based on clinical experience and guideline support, though not an FDA-labeled indication).
• Certain premature ejaculation protocols (off-label, low-dose or on-demand regimens described in urology literature).

Use of Serofit should always be guided by a qualified physician's assessment of the patient's diagnosis and risk-benefit profile.

Each tablet or capsule contains Sertraline Hydrochloride equivalent to a specified strength of sertraline base (commonly available as 25 mg, 50 mg, and 100 mg strengths). An oral concentrate/solution formulation is also available in some markets. Excipients vary by manufacturer and formulation.

Serofit is a selective serotonin reuptake inhibitor (SSRI), a class of antidepressant medicines. It works by increasing the availability of serotonin, a neurotransmitter involved in mood regulation, in the brain. Serofit is widely prescribed for depression and several anxiety-related disorders and is one of the most commonly used antidepressants worldwide due to its established efficacy and relatively favorable tolerability profile.

Serofit is available in tablet and capsule forms for oral administration, and in some markets as an oral concentrate solution.

Serofit belongs to the therapeutic class of Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants.

Pharmacodynamics

Sertraline Hydrochloride is a potent and selective inhibitor of neuronal serotonin (5-HT) reuptake at the presynaptic membrane. By blocking the serotonin transporter, it increases serotonin concentration in the synaptic cleft, enhancing serotonergic neurotransmission. Sertraline Hydrochloride has minimal effect on norepinephrine and dopamine reuptake and negligible affinity for muscarinic, histaminergic, or adrenergic receptors, which accounts for its comparatively favorable side-effect profile relative to older tricyclic antidepressants.

Pharmacokinetics

Sertraline Hydrochloride is slowly absorbed after oral administration, with peak plasma concentrations reached in approximately 4.5-8.4 hours. Food modestly increases bioavailability. It is extensively metabolized in the liver (primarily via CYP2C19, with contributions from CYP2B6, CYP2C9, CYP3A4, and CYP2D6) to its major metabolite, desmethylsertraline, which has substantially weaker pharmacological activity. Sertraline Hydrochloride is highly protein-bound (approximately 98%). The elimination half-life is approximately 26 hours (longer in the elderly and in hepatic impairment), and steady state is typically reached within about one week of once-daily dosing. Elimination occurs via hepatic metabolism, with metabolites excreted in roughly equal proportions in urine and feces.

Serofit tablets/capsules should be swallowed whole with a glass of water, once daily, at approximately the same time each day, with or without food. The oral concentrate (where available) must be diluted with a measured amount of water, ginger ale, lemon/lime soda, lemonade, or orange juice only, immediately before administration, and should not be mixed with anything else. Do not stop taking Serofit abruptly without consulting a physician, as this may cause discontinuation symptoms.

Serofit has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue: Concomitant use or use within 14 days of stopping either drug is contraindicated due to risk of serious, potentially fatal serotonin syndrome (see Contraindications).
• Pimozide: Contraindicated due to risk of QT-interval prolongation and serious cardiac arrhythmia (see Contraindications).
• Other serotonergic drugs (e.g., other SSRIs/SNRIs, triptans, tramadol, lithium, St. John's Wort, fentanyl): Increased risk of serotonin syndrome; concurrent use requires caution and close monitoring.
• NSAIDs, aspirin, warfarin, and other anticoagulants/antiplatelets: Increased risk of bleeding due to combined effects on platelet function and anticoagulation; use with caution and monitor for bleeding.
• CYP2C19/CYP2D6 substrates and inhibitors: Serofit can inhibit CYP2D6 and may increase plasma levels of drugs metabolized by this enzyme; strong CYP2C19 inhibitors may increase sertraline exposure.
• Alcohol: May increase central nervous system depressant effects; avoid or limit alcohol intake.
• Disulfiram: The oral concentrate formulation contains alcohol and should be avoided in patients taking disulfiram.

Common side effects of Serofit include:

• Nausea and other gastrointestinal upset (diarrhea, dyspepsia), especially early in treatment
• Dry mouth
• Insomnia or drowsiness
• Headache
• Dizziness
• Increased sweating
• Tremor
• Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia) - common and may persist
• Fatigue
• Appetite changes and weight changes

Less common but serious effects include serotonin syndrome, abnormal bleeding, hyponatremia, activation of mania/hypomania, seizures, and increased suicidal thinking (particularly in young people) - see Precautions and Warnings for details.

Pregnancy: Serofit should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Third-trimester exposure to SSRIs, including Serofit, has been associated with neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding (poor neonatal adaptation syndrome), and some studies have suggested a possible small increased risk of persistent pulmonary hypertension of the newborn. Untreated maternal depression also carries risks to the mother and fetus, so the decision to use Serofit in pregnancy should be individualized in consultation with a physician, weighing these risks.

Lactation: Serofit is excreted in human breast milk in small amounts. It may be used during breastfeeding if the expected benefit outweighs the potential risk to the infant; the infant should be monitored for irritability, feeding difficulty, and sedation. Consult a physician before use while breastfeeding.

Boxed Warning: Suicidal Thoughts and Behaviors

Serofit, like other antidepressants, carries a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24), particularly during the first few months of treatment or after dose changes. Patients of all ages should be monitored closely for clinical worsening, unusual behavior changes, and suicidality, especially early in treatment.

Serotonin Syndrome

Concomitant use of Serofit with other serotonergic agents increases the risk of serotonin syndrome (agitation, hallucinations, tachycardia, hyperthermia, tremor, incoordination); see Interactions and Contraindications.

Discontinuation Symptoms

Abrupt discontinuation of Serofit may cause dizziness, sensory disturbances, anxiety, agitation, and other symptoms. Doses should be tapered gradually under medical supervision rather than stopped suddenly.

Abnormal Bleeding

Serofit may impair platelet aggregation and increase the risk of bleeding events, particularly when combined with NSAIDs, aspirin, warfarin, or other anticoagulants.

Hyponatremia

Hyponatremia, sometimes severe, has been reported with SSRIs including Serofit, particularly in elderly patients and those on diuretics or with volume depletion.

Activation of Mania/Hypomania

Serofit should be used cautiously in patients with a history of bipolar disorder, as it may precipitate a manic or hypomanic episode; screening for bipolar disorder is recommended before starting treatment.

Other precautions

Use with caution in patients with a seizure disorder, hepatic impairment, or a history of QT prolongation. Serofit may cause sexual dysfunction (see Side Effects). Do not stop, skip, or alter the dose of Serofit without consulting a physician.

Overdose of Serofit, especially in combination with other drugs or alcohol, can cause serious effects including drowsiness, vomiting, tachycardia, tremor, agitation, dizziness, and in severe cases, serotonin syndrome, seizures, coma, and cardiac conduction abnormalities. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home; treatment is supportive and should be provided in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Serofit is approved for OCD in children and adolescents aged 6-17 years. Safety and efficacy for major depressive disorder and other indications have not been established in pediatric patients. Close monitoring for suicidality and behavioral changes is required (see Precautions and Warnings).

Elderly

Elderly patients may be more susceptible to hyponatremia and may have reduced clearance of Serofit; use with caution and monitor closely, though routine dose adjustment based on age alone is not typically required.

Hepatic Impairment

Reduced clearance occurs in hepatic impairment; a lower dose or reduced frequency of Serofit is recommended, with caution advised (see Dosage and Administration).

Renal Impairment

No dosage adjustment is generally needed in mild-to-moderate renal impairment; data in severe renal impairment are limited, so caution is advised.

The duration of treatment with Serofit depends on the indication and individual response. For major depressive disorder, treatment is typically continued for at least 6 months after achieving an adequate response to reduce the risk of relapse, and longer-term maintenance therapy may be recommended for patients with recurrent depression. For anxiety disorders, OCD, and PTSD, treatment duration is individualized based on response and physician judgment, often continuing for several months to years. When discontinuing Serofit, the dose should be tapered gradually under medical supervision rather than stopped abruptly.

Sertraline Hydrochloride is classified as an antidepressant, specifically within the Selective Serotonin Reuptake Inhibitor (SSRI) class.

Sertraline Hydrochloride selectively inhibits the presynaptic reuptake of serotonin (5-HT) in the central nervous system, increasing serotonin availability in the synaptic cleft and enhancing serotonergic neurotransmission, which is believed to underlie its antidepressant and anti-anxiety effects.

C

Serofit is approved for the treatment of Obsessive-Compulsive Disorder (OCD) in pediatric patients aged 6 to 17 years, with a lower starting dose in children (6-12 years: 25 mg/day) compared to adolescents (13-17 years: 50 mg/day), titrated as tolerated up to 200 mg/day. Safety and efficacy of Serofit have not been established in pediatric patients for major depressive disorder or other indications outside of OCD. All pediatric and adolescent patients started on Serofit require close monitoring for emergence or worsening of suicidal thinking and behavior, especially during the first few months of treatment (see Precautions and Warnings).